Streetbeat News

Products Services

OGEN

Oragenics Inc. (NYSE:OGEN) has completed the manufacturing of its spray-dried drug formulation and intranasal device filling for ONP-002, a treatment for concussions. The company is preparing for a Phase 2a clinical trial in Australia, aiming to enroll 40 patients. The trial will assess the drug's efficacy in reducing negative outcomes after a concussion.

Portfolio Pulse from Vandana Singh

August 21, 2024 | 12:30 pm

OGEN

Oragenics has announced that its drug, ONP-002, could potentially be the first pharmaceutical treatment available for concussions. Currently, there are no pharmaceutical treatments for concussions, highlighting the significance of this development.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:30 pm

OGEN

Oragenics has completed the spray dry drug manufacturing and intranasal device filling in preparation for a Phase IIa clinical trial targeting concussed patients.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:30 pm

BA

GCAD

ITA

Boeing's 777X jetliner faces delays due to structural cracks found during test flights, potentially pushing the launch to 2026. This adds to Boeing's ongoing challenges, including FAA inspections and regulatory issues. Boeing shares are slightly up premarket.

Portfolio Pulse from Lekha Gupta

August 21, 2024 | 12:16 pm

LRHC

La Rosa Holdings is launching a multi-level revenue share plan in Puerto Rico aimed at providing realtors with a unique income stream. This initiative is expected to empower realtors and potentially enhance the company's revenue.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:15 pm

MNPR

Monopar Therapeutics' stock is rising following the approval from Australia's human research ethics committee to begin a Phase 1 trial of its new radiopharmaceutical for advanced cancers.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:10 pm

LIPO

Lipella Pharmaceuticals shares are trading lower following the announcement that the company will present clinical data on LP-20 at an international conference in Japan.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:08 pm

LXRX

Lexicon Pharmaceuticals announced that the FDA will hold an advisory committee meeting on October 31, 2024, to discuss the approval of Zynquista for use in adults with type 1 diabetes and chronic kidney disease. The PDUFA goal date is set for December 20, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:06 pm

FL

NKE

Foot Locker is set to reopen its iconic 34th Street store in NYC, introducing a 'Home Court' multi-brand basketball destination in partnership with Nike and Jordan Brand. The store will feature immersive experiences and enhanced technology.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:06 pm

F

Ford plans to expand its fully-electric portfolio by introducing a new commercial van in 2026, followed by two new pickup trucks in 2027, along with other affordable electric vehicles.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:06 pm